Immunoimaging of CXCR4 Expression in Brain Tumor Xenografts Using SPECT/CT

Overview

Journal J Nucl Med

Specialty Nuclear Medicine

Date 2009 Jun 16

PMID 19525448

Citations 38

Authors

Sridhar Nimmagadda

Mrudula Pullambhatla

Martin G Pomper

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Chemokine receptor 4 (CXCR4) is expressed in a variety of cancers, including breast, brain, ovarian, and prostate. CXCR4-CXCL12 interactions are critical for tumor development, growth, and metastasis. Compared with normal tissue, neoplastic tissue (including metastases) expresses high levels of CXCR4. Previous clinical and preclinical observations suggest that CXCR4 levels could be used as a predictive marker of metastatic potential. Here we report the results of SPECT/CT of CXCR4 expression levels in experimental brain tumors using (125)I-labeled anti-CXCR4 monoclonal antibodies (mAbs).

Methods: hCXCR4 antibody 12G5 and control IgG(2A) antibody were radiolabeled. Radio-mAbs were obtained in 40%-60% yield, with 1.4-1.9 MBq/microg specific radioactivities and greater than 95% purity. Severe combined immunodeficient mice harboring U87 xenografts were used for ex vivo biodistribution and imaging studies. Surface CXCR4 expression levels on U87 tumor-derived cells were analyzed by flow cytometry.

Results: Biodistribution and imaging studies showed a specific accumulation of (125)I-12G5 in U87 tumors, with tumor-to-muscle uptake ratios reaching 15 +/- 3 at 48 h after injection. The tumor-to-tumor uptake ratio for (125)I-12G5 and (125)I-IgG(2A) was 2.5 at 48 h after injection. Flow cytometry analysis of tumor-derived cells showed a 2- to 7-fold increase in CXCR4 expression relative to inoculums, accounting for the high mAb uptake observed in the tumors.

Conclusion: Our data demonstrate the feasibility of imaging CXCR4 expression in experimental brain tumors. The elevated CXCR4 levels observed may have been, in part, due to the hypoxic tumor microenvironment.

Citing Articles

The Role of [Ga]Ga-Pentixafor PET/CT or PET/MRI in Lymphoma: A Systematic Review.

Albano D, Dondi F, Bertagna F, Treglia G Cancers (Basel). 2022; 14(15).

PMID: 35954476 PMC: 9367619. DOI: 10.3390/cancers14153814.

CXCR4-targeted theranostics in oncology.

Buck A, Serfling S, Lindner T, Hanscheid H, Schirbel A, Hahner S Eur J Nucl Med Mol Imaging. 2022; 49(12):4133-4144.

PMID: 35674738 PMC: 9525349. DOI: 10.1007/s00259-022-05849-y.

An Evaluation of CXCR4 Targeting with PAMAM Dendrimer Conjugates for Oncologic Applications.

Lesniak W, Azad B, Chatterjee S, Lisok A, Pomper M Pharmaceutics. 2022; 14(3).

PMID: 35336029 PMC: 8953329. DOI: 10.3390/pharmaceutics14030655.

Investigating CXCR4 expression of tumor cells and the vascular compartment: A multimodal approach.

Braga M, Leow C, Gil J, Teh J, Carroll L, Long N PLoS One. 2021; 16(11):e0260186.

PMID: 34793563 PMC: 8601444. DOI: 10.1371/journal.pone.0260186.

The biological role of the CXCL12/CXCR4 axis in esophageal squamous cell carcinoma.

Wu X, Zhang H, Sui Z, Wang Y, Yu Z Cancer Biol Med. 2021; .

PMID: 33710803 PMC: 8185864. DOI: 10.20892/j.issn.2095-3941.2020.0140.

References

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

Jones P, Brown B, SANDS H . Uptake and metabolism of 111In-labeled monoclonal antibody B6.2 by the rat liver. Cancer Res. 1990; 50(3 Suppl):852s-856s. View

Rubin J, Kung A, Klein R, Chan J, Sun Y, Schmidt K . A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A. 2003; 100(23):13513-8. PMC: 263845. DOI: 10.1073/pnas.2235846100. View

McKnight A, Wilkinson D, Simmons G, Talbot S, Picard L, Ahuja M . Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. J Virol. 1997; 71(2):1692-6. PMC: 191233. DOI: 10.1128/JVI.71.2.1692-1696.1997. View

Kim K, Wang L, Su Y, Gillespie G, Salhotra A, Lal B . Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res. 2006; 12(4):1292-8. DOI: 10.1158/1078-0432.CCR-05-1793. View

Ehtesham M, Winston J, Kabos P, Thompson R . CXCR4 expression mediates glioma cell invasiveness. Oncogene. 2006; 25(19):2801-6. DOI: 10.1038/sj.onc.1209302. View

Zagzag D, Lukyanov Y, Lan L, Ali M, Esencay M, Mendez O . Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest. 2006; 86(12):1221-32. DOI: 10.1038/labinvest.3700482. View

Woo S, Bae J, Kim C, Lee J, Koo B . A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer. Ann Surg Oncol. 2007; 15(1):281-5. DOI: 10.1245/s10434-007-9595-1. View

10.

Carnec X, Quan L, Olson W, Hazan U, Dragic T . Anti-CXCR4 monoclonal antibodies recognizing overlapping epitopes differ significantly in their ability to inhibit entry of human immunodeficiency virus type 1. J Virol. 2005; 79(3):1930-3. PMC: 544137. DOI: 10.1128/JVI.79.3.1930-1933.2005. View

11.

Rempel S, Dudas S, Ge S, Gutierrez J . Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res. 2000; 6(1):102-11. View

12.

Helbig G, Christopherson 2nd K, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller K . NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem. 2003; 278(24):21631-8. DOI: 10.1074/jbc.M300609200. View

13.

Hanaoka H, Mukai T, Tamamura H, Mori T, Ishino S, Ogawa K . Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. Nucl Med Biol. 2006; 33(4):489-94. DOI: 10.1016/j.nucmedbio.2006.01.006. View

14.

Gupta S, Pillarisetti K . Cutting edge: CXCR4-Lo: molecular cloning and functional expression of a novel human CXCR4 splice variant. J Immunol. 1999; 163(5):2368-72. View

15.

Zalutsky M, Moseley R, Coakham H, Coleman R, Bigner D . Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res. 1989; 49(10):2807-13. View

16.

Schioppa T, Uranchimeg B, Saccani A, Biswas S, Doni A, Rapisarda A . Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med. 2003; 198(9):1391-402. PMC: 2194248. DOI: 10.1084/jem.20030267. View

17.

Kato M, Kitayama J, Kazama S, Nagawa H . Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res. 2003; 5(5):R144-50. PMC: 314431. DOI: 10.1186/bcr627. View

18.

Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, Simon R . The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat. 2005; 97(3):275-83. DOI: 10.1007/s10549-005-9121-8. View

19.

Linden H, Stekhova S, Link J, Gralow J, Livingston R, Ellis G . Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006; 24(18):2793-9. DOI: 10.1200/JCO.2005.04.3810. View

20.

Benard F, Turcotte E . Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography. Breast Cancer Res. 2005; 7(4):153-62. PMC: 1175073. DOI: 10.1186/bcr1201. View